Conference Archive
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Intismeran Plus Pembrolizumab Improves RFS in Melanoma
3
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5